Page last updated: 2024-12-08

cadmium metallothionein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cadmium-binding protein: metallothionein which serves in a metal-sequestering mechanism [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID198548
MeSH IDM0045189

Synonyms (7)

Synonym
cadmium-thionein
cadmium-metallothionen
cadmium-binding protein
73419-42-8
DTXSID90994141
cadmium bis[3-(2-sulfido-1h-imidazol-5-yl)-2-(trimethylazaniumyl)propanoate]
cadmium(2+);3-(2-sulfido-1h-imidazol-5-yl)-2-(trimethylazaniumyl)propanoate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These models can be used to estimate the dose levels of Zn and Cu which will reduce the toxic effects of CdMT."( A multivariate study of protective effects of Zn and Cu against nephrotoxicity induced by cadmium metallothionein in rats.
Jin, TY; Liu, XY; Nordberg, GF; Rännar, S; Sjöström, M; Zhou, Y, 1992
)
0.5
" There was no adverse effect on general health or survival."( Comparison of the toxicity of inorganic and liver-incorporated cadmium: a 4-wk feeding study in rats.
Groten, JP; Luten, JB; Sinkeldam, EJ; van Bladeren, PJ, 1990
)
0.28
" In Fe-deficient animals, cadmium was found to be more toxic than in Fe supplemented animals as measured by growth."( Studies on the role of iron in the reversal of cadmium toxicity in chicks.
Blalock, TL; Hill, CH,
)
0.13
" CdMT has also been demonstrated to be more toxic than Cd in cultured kidney cells, but it is not known if CdMT is more toxic to all cultured cells or if there is a good correlation between in vitro and in vivo toxicity."( Comparisons of the toxicity of CdCl2 and Cd-metallothionein in isolated rat hepatocytes.
Bracken, WM; Klaassen, CD; Sendelbach, LE, 1989
)
0.28
" The biological half-time of cadmium in the human kidney is considered to be very long: 10-15 years and this explains the life-long accumulation of cadmium, reaching a toxic concentration of approximately 200 ug/g in excessively exposed individuals."( On the role of metallothionein in cadmium induced renal toxicity.
Nordberg, GF; Nordberg, M, 1987
)
0.27
" Upon exposure to CdCl2 in vitro (0-200 micrograms Cd/ml), a concentration dependent decrease in viability was observed in the non-pretreated cells, while no such decrease occurred in the pretreated cells indicating that these cells were more resistant to the toxic action of cadmium."( Influence of cadmium-metallothionein pretreatment on tolerance of rat kidney cortical cells to cadmium toxicity in vitro and in vivo.
Jin, T; Nordberg, GF; Nordberg, M, 1987
)
0.27
"Evaluation of the potential adverse human health effects of low-level chronic exposure to heavy metals is dependent on the basic knowledge of the cellular and molecular toxicology of these metals."( Rat kidney epithelial cell culture for metal toxicity studies.
Cherian, MG, 1985
)
0.27
"Nephrotoxicity is the major adverse effect produced by chronic exposure to cadmium (Cd)."( Nephrotoxicity of CdCl2 and Cd-metallothionein in cultured rat kidney proximal tubules and LLC-PK1 cells.
Klaassen, CD; Liu, J; Liu, Y, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" A dose-response increase in MT produced by CdCl2 indicated a biphasic response, with low doses producing relatively more hepatic MT than higher doses."( Induction of metallothionein by cadmium-metallothionein in rat liver: a proposed mechanism.
Klaassen, CD; Liu, J; Liu, YP; McKim, JM, 1992
)
0.28
" Hepatic and renal metallothionein (MT) concentrations were increased with increasing dosage of CdMT, and no differences between strains were demonstrated."( Cd-metallothionein nephrotoxicity in inbred strains of mice.
Cuppage, F; Kershaw, WC; Klaassen, CD; Sendelbach, LE, 1992
)
0.28
" In animals that are dosed with either of the heterologous MT preparations, the first dose, although not innocuous, seems to protect the kidneys against further damage by subsequent doses."( The chronic toxicity of equine cadmium metallothionein in the rat.
Holt, D; Sparrow, S; Webb, M, 1985
)
0.56
" Apical vesiculation in epithelial cells of the renal proximal convoluted tubules is apparent within 1 h of dosing and, by 4 h, is extensive in some of these cells that surround the larger arteries in the cortex."( Cadmium-metallothionein-induced nephropathy: a morphological and autoradiographic study of cadmium distribution, the development of tubular damage and subsequent cell regeneration.
Cain, K; Murakami, M; Webb, M, 1983
)
0.27
" The results of the activities changes of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), and blood urea nitrogen (BUN) in plasma showed that the hepatotoxicity of coexposure was lower than that of single exposure, and the hepatotoxicity and accumulation of oMWCNTs in livers depended strongly on the exposure dosage of oMWCNTs."( The effect of multiwalled carbon nanotubes on hepatotoxicity of Cd2+ in accumulated cadmium-metallothione in mice.
Juanjuan, B; Longlong, T; Peng, L; Wangsuo, W; Wei, Q; Zhan, L, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (292)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990132 (45.21)18.7374
1990's105 (35.96)18.2507
2000's28 (9.59)29.6817
2010's22 (7.53)24.3611
2020's5 (1.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.28 (24.57)
Research Supply Index5.72 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (2.31%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other296 (97.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]